Market Overview

Tickers

Articles

Keywords

Search by keyword...
googlecse

Quotes

Analysis

Analyst Ratings

News

Press Releases

Twitter

Media Mentions

Ownership

Earnings

InterMune, Inc. (ITMN) 10.75 -0.31
Price Open:10.41Day's Range:0.00000 - 10.81000
Price Close:10.3052wk Range:0.00000 - 27.23
Price Day Change:-0.31Volume:1,541,438
Price % Change:-3.01Market Cap:816.0M
Bid:9.70000PE Ratio:0
Ask:10.75000EPS Diluted:-2.338
Trade ITMN NOW!

The Latest On ITMN

Mid-Morning Market Update: Markets Tumble, Oracle Posts Downbeat Results 3/21/13 10:41am
National Institute for Health and Clinical Excellence in England and Wales Recommends Esbriet for Mild to Moderate IPF 3/21/13 5:59am
UPDATE: Stifel Nicolaus Cuts PT to $17 on InterMune Following Guidance 2/22/13 2:20pm
InterMune Shares Sink as Co. Announces Concurrent Offering of 12.5M Shares of Stock, $85M in Debt 1/15/13 10:39am
UPDATE: Stifel Nicolaus Cuts PT to $19 on InterMune on Esbriet Pre-Announcement 1/4/13 2:33pm
InterMune Reports Preliminary Fourth Quarter 2012 Esbriet Revenue And Other Recent Business Highlights 1/3/13 5:05pm
InterMune Soars 19 Percent After Q3 Earnings Results 11/8/12 5:46pm
Mid-Afternoon Market Update: Stocks Remain Lower 11/8/12 4:37pm
UPDATE: Canaccord Genuity Upgrades InterMune to Buy on Esbriet EU Momentum 11/8/12 9:49am
Benzinga Mid-Day Market Update 10/3/12 2:38pm
Health Canada Approves Esbriet as First Treatment for Fatal Lung Disease 10/2/12 4:06pm
InterMune Reports New Analyses from the RECAP Study of Esbriet at ERS 9/3/12 11:01am
more
Press Releases
Critical Alerts For Pfizer, CBS, International Paper, Youku.com, and InterMune Released By InvestorsObserver 5/14/13 Newswire
InterMune To Release First Quarter Financial Results On April 24 4/17/13 Newswire
Esbriet® (pirfenidone) Receives Positive Final Appraisal Determination from NICE for Idiopathic Pulmonary Fibrosis (IPF) 3/20/13 Newswire
InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights 2/21/13 Newswire
Sean P. Nolan Joins InterMune as Executive Vice President and Chief Business Officer 2/14/13 Newswire
InterMune To Release Fourth Quarter Financial Results On February 21 2/11/13 Newswire
InterMune Announces Pricing of Concurrent Public Offerings of $105,000,000 Principal Amount of Convertible Senior Notes and 13,500,000 Shares of Common Stock 1/16/13 Newswire
InterMune Announces Proposed Concurrent Public Offerings Of Common Stock And Convertible Debt 1/14/13 Newswire
InterMune Reports Preliminary Fourth Quarter 2012 Esbriet® (pirfenidone) Revenue And Other Recent Business Highlights 1/3/13 Newswire
InterMune To Present At J. P. Morgan Healthcare Conference 1/2/13 Newswire
As Competitors Pursue Alternatives One Biotech Gains Prominence for its Potential to Treat Hepatitis 12/14/12 PR Thomson Reuters
As Competitors Pursue Alternatives One Biotech Gaining Prominence for Potential to Treat Hepatitis 12/14/12 PR Thomson Reuters

Get the latest ITMN stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for InterMune, Inc. stock price.

Partner Headlines
InterMune Cuts Loss, Affirms View - Analyst Blog 4/25/13
NICE News for InterMune - Analyst Blog 3/22/13
Wider Loss at InterMune - Analyst Blog 2/22/13
InterMune Prices Public Offerings - Analyst Blog 1/18/13
InterMune to Raise Funds - Analyst Blog 1/16/13
InterMune Inc. Reports Operating Results (10-Q) 11/9/12
Loss at ITMN Narrower than Expected - Analyst Blog 11/8/12
InterMune's Esbriet OK'd in Canada - Analyst Blog 10/3/12
French Reimbursement for Esbriet - Analyst Blog 9/13/12
Positive RECAP for ITMN's Esbriet - Analyst Blog 9/4/12
Manchester United, InterMune Among Stocks hitting 52-Week Lows Monday 8/20/12
Facebook Inc. - Class A, Molycorp Among Stocks falling to Annual Lows Friday 8/17/12